Global Hyperhidrosis Treatment Market - 2023-2030

Overview

Global Hyperhidrosis Treatment Devices Market reached US$ 450.2 million in 2022 and is expected to reach US$ 894.1 million by 2030, growing with a CAGR of 4.5% during the forecast period 2023-2030.

Hyperhidrosis is a chronic condition characterized by excessive and uncontrollable sweating. This excessive sweating associated with hyperhidrosis is normally most active in the hands, feet, armpits, and groin because of their relatively high concentration of sweat glands. The increase in the number of treatment approvals and the number of launches of drugs and topical treatments are driving the market growth.

The North America region is expected to hold a significant position in the market share. The Botulinum Toxin A segment holds a significant market share. The increased number of launches and the advantages of the treatment method are expected to hold the segment in the leading position.

Dynamics

Rise in the Prevalence of Hyperhidrosis is Expected to Accelerate the Market Growth

The increase in the prevalence of hyperhidrosis is expected to drive the market growth. For instance, according to the article published in NIH, it is expected that 3% of United States individuals suffer from hyperhidrosis. Primary hyperhidrosis, a specific classification of the disease, primarily affects younger adults aged 18 to 39 years, and it often has a genetic component.

Additionally, in Germany, the prevalence of hyperhidrosis is expected to be 16*3%, including 6*1% of patients with frequent or continuous disturbing sweating. It ranges in severity from being a little bit damp to extreme dripping. Therefore, hyperhidrosis can substantially impair the quality of life (QoL) of affected patients, such as limitations in daily activities, social relationships, study and work, and life and emotional well-being. People shift to the treatment and medication of hyperhidrosis, thus increasing the demand for treatment procedures. These factors are expected to drive the market growth.

Increase in the Number of Launches is Expected to Drive the Market Growth

An increase in the number of launches of devices for the treatment of hypohidrosis is expected to drive market growth. For instance, on October 7, 2022, Dermadry launched a revamped range of its best-selling iontophoresis devices to treat excessive sweating (hyperhidrosis) of the hands, feet, and underarms. This device has been reimagined for a seamless, comfortable, and effortless treatment experience suited for the millions of people affected by hyperhidrosis globally.

Additionally, on May 23, 2022, Maruho Co., Ltd. launched "Rapifort Wipes 2.5%" for the treatment of primary axillary hyperhidrosis in Japan. The active ingredient, glycopyrronium tosilate hydrate, reduces sweat production by blocking the activation of acetylcholine receptors in sweat glands. Thus, the launches of the products are expected to drive the market growth of the market.

Side Effects Associated with the Treatment can Hamper the Market Growth

Side effects associated with oral drugs are expected to hamper the market growth. Some pills (oral medications) block the nerves that trigger sweat glands. This can reduce sweating in some people. Possible side effects include dry mouth, blurred vision, bladder problems and complications with urination, confusion, dizziness, drowsiness or sandy feeling in the eyes, eye sensitivity to light, increased bloated feeling, constipation, dry skin, and rapid heartbeat.

Segment Analysis

The global hyperhidrosis treatment market is segmented based on disease type, treatment type, end-user, and region.

Botulinum Toxin A Segment Holds a Significant Position in the Market Share

Botulinum toxin A is expected to hold a significant position in the market share. The increased number of launches of the Botulinum toxin A (Botox) injections is expected to drive segment growth. For instance, on December 29, 2022, Gufic Biosciences launched the Botulinum toxin type A injection 'Zarbot,' developed and manufactured in collaboration with the United States (US)-based Prime Bio.

Additionally, the advantages of the treatment by injecting Botox over the other types of treatments are expected to hold the segment in a significant position. Botox injections have come to be widely used in managing primary hyperhidrosis when topical treatments have failed. The treatment works by blocking the nerve signals that instruct the sweat glands to become active.

It takes three to four days for the results of Botox injections for hyperhidrosis to become evident. According to the International Hyperhidrosis Society, people who receive Botox injections have found excessive sweating decreases by more than 85%. Thus, the above factors are expected to drive the segment growth.

Geographical Penetration

North America Holds the Largest Market Share in the Global Hyperhidrosis Market

North America holds a dominant force in the hyperhidrosis market. An increase in FDA approvals helps the manufacturers launch the products, and that increases profits for the company. For instance, on April 13, 2023, the US Food and Drug Administration (FDA) cleared Candesant Biomedical's Brella, 3-Minute SweatControl Patch for the treatment of adult patients with primary axillary hyperhidrosis.

Furthermore, on March 27, 2023, Hisamitsu Pharmaceutical Co., Inc. obtained FDA approval for the manufacturing and marketing of APOHIDE Lotion 20% for Japan's primary palmar hyperhidrosis treatment drug. Thus, increasing FDA approvals of the treatments is expected to drive the region's market growth.

Competitive Landscape

The global hyperhidrosis treatment market is fragmented, with the presence of many local and international players. LGM Pharma, GlaxoSmithKline, REVANCE AESTHETICS, Strides Pharma Science Limited, MANUS AKTTEVA BIOPHARMA LLP, Dr. August Wolff Gmbh & Co, SLUCARE, Kaken Pharmaceutical Co., Ltd., Fengchen Group Co., Ltd, and Advin Health Care are the leading Companies with a significant market share.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global hyperhidrosis market growth. The COVID-19 pandemic caused disruption in drug manufacturing for non-essential treatments. This has influenced the market growth.

The supply chains have been affected, which affected the product deliveries to the patients, and the availability of the drugs has been reduced. Surgical procedures such as iontophoresis have been delayed and postponed, thus creating a negative impact on market growth. Thus, COVID-19 has influenced the market growth negatively.

By Disease Type

• Primary Focal Hyperhidrosis
• Secondary Generalized Hyperhidrosis

By Treatment Type

• Topical Treatments
• Botulinum Toxin A
• Iontophoresis
• Surgical Treatment
• Others

By End-User

• Hospitals
• Ambulatory Surgical Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Why Purchase the Report?

• To visualize the global hyperhidrosis treatment market segmentation based on disease type, treatment type, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hyperhidrosis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global hyperhidrosis treatment market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies